Nature Search

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

An immunotherapy consisting of a tumor-antigen targeting antibody, PD-1 blocking antibody, extended half-life recombinant IL-2 and a lymph-node-targeted T cell vaccine mobilized innate and adaptive immunity and eradicated large established tumors in a variety of mouse models.

Kelly D Moynihan
Cary F Opel
Darrell J Irvine
Research24 Oct 2016
Nature Medicine

Volume: 22, P: 1402-1410
High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry

Assessing nanomaterials at the single cell level has proven to be complicated due to the limitations of existing techniques. Here, the authors utilised single-cell mass cytometry by time-of-flight as a label-free technique to analyse nanoparticle distribution within cells.

Yu-Sang Sabrina Yang
Prabhani U. Atukorale
Darrell J. Irvine
ResearchOpen Access17 Jan 2017
Nature Communications

Volume: 8, P: 1-11
Erratum: High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry

Yu-Sang Sabrina Yang
Prabhani U Atukorale
Darrell J Irvine
Amendments and CorrectionsOpen Access14 Aug 2017
Nature Communications

Volume: 8, P: 1-2
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

Mota et al. show that poor response to immune checkpoint blockade in mouse models of ALK-rearranged NSCLC can be overcome by vaccination with an immunogenic ALK peptide and identify immunogenic human ALK peptides for future translational study.

Ines Mota
Enrico Patrucco
Roberto Chiarle
Research10 Jul 2023
Nature Cancer

Volume: 4, P: 1016-1035
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy

Type 1 regulatory T cells (Tr1) represent a major obstacle that compromises naturally occurring and therapeutically induced tumour-specific immunity.

Hussein Sultan
Yoshiko Takeuchi
Robert D. Schreiber
ResearchOpen Access24 Jul 2024
Nature

Volume: 632, P: 182-191
Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines

Tuning the pharmacokinetics of peptide-based antitumour vaccines by fusing the peptide epitopes to protein carriers optimizes the immunogenicity of the vaccines in mice.

Naveen K. Mehta
Roma V. Pradhan
Darrell J. Irvine
Research01 Jun 2020
Nature Biomedical Engineering

Volume: 4, P: 636-648
Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy

A delay in T cell responses is postulated as a possible explanation for the limited efficacy of vaccines against tuberculosis. Here the authors demonstrate this T-cell block and remove it by activating endogenous dendritic cells or delivering activated dendritic cells to the lungs, enhancing immunity of mice toMycobacterium tuberculosis.

Kristin L. Griffiths
Mushtaq Ahmed
Shabaana A. Khader
ResearchOpen Access22 Dec 2016
Nature Communications

Volume: 7, P: 1-13
Structure-based programming of lymph-node targeting in molecular vaccines

An amphiphile vaccine consisting of a peptide antigen or adjuvant cargo linked to a lipophilic tail is shown to have improved potency and safety in mice by targeting the lymph nodes.

Haipeng Liu
Kelly D. Moynihan
Darrell J. Irvine
Research16 Feb 2014
Nature

Volume: 507, P: 519-522

Search

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry

Erratum: High-throughput quantitation of inorganic nanoparticle biodistribution at the single-cell level using mass cytometry

ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer

Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy

Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines

Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy

Structure-based programming of lymph-node targeting in molecular vaccines

Search

Quick links

Search

Filter By:

Search

Quick links